To include your compound in the COVID-19 Resource Center, submit it here.

Meropenem/vaborbactam: Phase III data

Top-line data from 374 patients with cUTI or acute pyelonephritis in the microbiologic mITT population of the double-blind, double-dummy, international Phase III TANGO 1 trial showed that 2 g/2 g Carbavance meropenem/vaborbactam

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE